Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 7, 2011, Pages 492-498

  Rosenberger, D ^a   Gargoum, R ^a   Tyagi, N ^a   Metreveli, N ^a   Sen, U ^a   Maldonado, C ^a   Tyagi, S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Atrioventricular conduction; Cardiac connexin; Homocysteine; Long QTc interval; Matrix metalloproteinase

Indexed keywords

GAP JUNCTION PROTEIN; GELATINASE A; GELATINASE B; HOMOCYSTEINE; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE;

ANIMAL; ARTICLE; BLOOD; C57BL MOUSE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DIET; DISEASE MODEL; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERHOMOCYSTEINEMIA; MALE; METABOLISM; MOUSE; NERVE CONDUCTION; PATHOPHYSIOLOGY; RANDOMIZATION; TELEMETRY;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CONNEXINS; DIET; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HEART VENTRICLES; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEURAL CONDUCTION; RANDOM ALLOCATION; TELEMETRY; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

ANIMALIA; MUS;

EID: 79959521169     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.11.014     Document Type: Article

References (27)

1. Bostom A.G., Rosenberg I.H., Silbershatz H., Jacques P.F., Selhub J., D'Agostino R.B., et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999, 131. 352-325.
2. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230-236.
3. Homocysteine Trabetti E. MTHFR gene polymorphisms, and cardio-cerebrovascular risk. J Appl Genet 2008, 49:267-282.
4. Rakhit D.J., Marwick T.H., Armstrong K.A., Johnson D.W., Leano R., Isbel N.M. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006, 92:1402-1408.
5. Rosenberger D., Moshal K.S., Kartha G.K., Tyagi N., Sen U., Lominadze D., et al. Arrhythmia and neuronal/endothelial myocyte uncoupling in hyperhomocysteinemia. Arch Physiol Biochem 2006, 112:219-227.
6. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8:221-233.
7. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
8. Retterstol L., Paus B., Bohn M., Bakken A., Erikssen J., Malinow M.R., et al. Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: a 10-year follow-up study. J Intern Med 2003, 253:284-292.
9. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006, 113:e409-e449.
10. Malinow M.R., Kang S.S., Taylor L.M., Wong P.W., Coull B., Inahara T., et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989, 79:1180-1188.
11. Brouillette J., Grandy S.A., Jolicoeur P., Fiset C. Cardiac repolarization is prolonged in CD4C/HIV transgenic mice. J Mol Cell Cardiol 2007, 43:159-167.
12. Remme C.A., Verkerk A.O., Nuyens D., van Ginneken A.C., van Brunschot S., Belterman C.N., et al. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 2006, 114:2584-2594.
13. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
14. Stubbs P.J., Al-Obaidi M.K., Conroy R.M., Collinson P.O., Graham I.M., Noble I.M. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000, 102:605-610.
15. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Schouten E.G. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002, 288:2023-2031.
16. Rossi G.P., Seccia T.M., Pessina A.C. Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?. Clin Chem Lab Med 2007, 45:1645-1651.
17. Moshal K.S., Singh M., Sen U., Rosenberger D.S., Henderson B., Tyagi N., et al. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006, 291:H2825-H2835.
18. Saffitz J.E., Laing J.G., Yamada K.A. Connexin expression and turnover: implications for cardiac excitability. Circ Res 2000, 86:723-728.
19. Severs N.J., Bruce A.F., Dupont E., Rothery S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res 2008, 80:9-19.
20. Beauchamp P., Yamada K.A., Baertschi A.J., Green K., Kanter E.M., Saffitz J.E., et al. Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. Circ Res 2006, 99:1216-1224.
21. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.
22. Clarke R., Lewington S., Sherliker P., Armitage J. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care 2007, 10:32-39.
23. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
24. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmal R., Hart R.G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155:469-473.
25. Flaker G.C., Belew K., Beckman K., Vidaillet H., Kron J., Safford R., et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005, 149:657-663.
26. Colucci M., Cattaneo M., Martinelli I., Semeraro F., Binetti B.M., Semeraro N. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemost 2008, 6:1571-1577.
27. Haim M., Tanne D., Goldbourt U., Doolman R., Boyko V., Brunner D., et al. Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease. Cardiology 2007, 107:52-56.